| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | MYD88; Myeloid differentiation primary response protein MyD88 |
| Entrez GeneID | 4615 |
| WB Predicted band size | Calculated MW: 33 kDa; Observed MW: 33 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | The antiserum was produced against synthesized peptide derived from human MyD88. AA range:171-220 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于MyD88抗体的3篇代表性文献，涵盖不同研究方向：
1. **文献名称**：*MyD88 self-association dynamics revealed by fluorescence anisotropy and crystallographic studies*
**作者**：Valkov E. et al.
**摘要**：通过晶体学分析和荧光各向异性技术，研究了MyD88蛋白的自身寡聚化机制，并利用特异性抗体验证其结构域相互作用，揭示了MyD88在TLR信号通路中的关键构象变化。
2. **文献名称**：*Targeted sequencing reveals activating mutations in MyD88 and other lymphomagenesis genes in diffuse large B-cell lymphoma*
**作者**：Ngo V.N. et al.
**摘要**：研究使用MyD88抗体检测弥漫大B细胞淋巴瘤(DLBCL)患者样本，发现MyD88 L265P突变与NF-κB通路异常激活相关，为靶向治疗提供了分子标志物依据。
3. **文献名称**：*A highly specific anti-MyD88 antibody suppresses IgE-mediated anaphylaxis and collagen-induced arthritis in preclinical models*
**作者**：Kawasaki T. et al.
**摘要**：开发了一种高特异性人源化MyD88抗体，通过阻断MyD88与TLR/IL-1R下游分子相互作用，显著抑制IgE介导的过敏反应和类风湿性关节炎模型中的炎症反应。
如需具体DOI或发表年份，可进一步补充检索条件。
MyD88 (Myeloid Differentiation Primary Response 88) is a critical adaptor protein in innate immune signaling, primarily involved in Toll-like receptor (TLR) and Interleukin-1 receptor (IL-1R) pathways. Upon ligand binding, MyD88 recruits downstream kinases to initiate signaling cascades that activate NF-κB and MAPK pathways, driving pro-inflammatory cytokine production. MyD88 antibodies are essential tools for studying these processes, enabling detection and quantification of MyD88 expression in various experimental settings, such as Western blotting, immunohistochemistry, and flow cytometry.
Research applications include investigating immune disorders, infections, and cancers. For example, MyD88 mutations (e.g., L265P in the TIR domain) are linked to lymphomas like Waldenström’s macroglobulinemia, making MyD88 antibodies vital for diagnostic assays. These antibodies also help explore MyD88's role in autoimmune diseases, sepsis, and cancer immunotherapy, where TLR/MyD88 signaling modulation is therapeutic.
Commercial MyD88 antibodies vary in specificity, targeting epitopes like full-length proteins, phosphorylated forms, or mutant variants. Validation across species (human, mouse, rat) and sample types (cell lysates, tissues) ensures broad applicability. Recent studies also use MyD88 inhibitors alongside antibodies to dissect pathway mechanisms. Overall, MyD88 antibodies are indispensable for advancing immunology research and developing targeted therapies.
×
